Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy
| العنوان: | Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy |
|---|---|
| المؤلفون: | Jay Slyer, Thomas Grace |
| المصدر: | Diabetes Technology & Therapeutics |
| بيانات النشر: | Mary Ann Liebert Inc, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Blood Glucose, Blood glucose testing, medicine.medical_specialty, HbA1c, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Population, Glycemic Control, Type 2 diabetes, Endocrinology, Noninsulin medications, Diabetes mellitus, Intensive therapy, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Basal insulin, Prospective Studies, education, Glycemic, Glycated Hemoglobin, education.field_of_study, CGM, Continuous glucose monitoring, business.industry, Blood Glucose Self-Monitoring, Original Articles, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Glucose, Diabetes Mellitus, Type 2, Time in range, business |
| الوصف: | Objective: Use of real-time continuous glucose monitoring (rtCGM) has been shown to improve glycemic control in patients with type 2 diabetes (T2D) who are treated with intensive insulin therapy. However, most T2D patients are denied coverage for rtCGM due to failure to meet payer eligibility requirements: treatment with ≥3 insulin injections (or pump) and history of 4 × /day blood glucose testing. We investigated the relevance of these criteria to successful rtCGM use. Methods: This 6-month, prospective, interventional, single-arm study assessed the clinical effects of use rtCGM in patients with T2D treated with basal insulin only or noninsulin therapy. Primary outcomes were changes in HbA1c, average glucose, glycemic variability (% coefficient of variation), and percent of time in range (%TIR), below range (%TBR) and above range (%TAR). Results: Thirty-eight patients were included in the analysis (10.1% ± 1.8% HbA1c, 54.7 ± 10.2 years, 35.6 ± 6.4 body mass index). At 6 months, we observed reductions in HbA1c (−3.0% ± 1.3%, P |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7554c1cb2a5abd383a503f94e2c5d5f2Test https://doi.org/10.1089/dia.2021.0212Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7554c1cb2a5abd383a503f94e2c5d5f2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|